EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+10.4%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$970M
AUM Growth
+$970M
(+5%)
Cap. Flow
-$13.8M
Cap. Flow
% of AUM
-1.42%
Top 10 Holdings %
Top 10 Hldgs %
72%
Holding
47
New
11
Increased
8
Reduced
10
Closed
10
Top Buys
| 1 |
FibroGen
FGEN
|
$60.7M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$44.9M |
| 3 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
$31.6M |
| 4 |
BCEL
Atreca, Inc. Class A Common Stock
BCEL
|
$28M |
| 5 |
ARQL
Arqule Inc
ARQL
|
$14.3M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$42.5M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$41.4M |
| 3 |
argenx
ARGX
|
$34.5M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$24.9M |
| 5 |
Assembly Biosciences
ASMB
|
$22.7M |
Sector Composition
| 1 | Healthcare | 88.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Kura Oncology
KURA
$686M
| $104M | 10.5% | 5,276,753 | – | – |
|
2
Xencor
XNCR
$580M
| $95.6M | 9.66% | 2,336,557 +277,128 | +13% | +$11.3M |
|
|
3
argenx
ARGX
$43.6B
| $82.3M | 8.31% | 581,165 -243,922 | -30% | -$34.5M |
|
4
CRISPR Therapeutics
CRSP
$4.71B
| $75.8M | 7.66% | 1,610,250 -268,027 | -14% | -$12.6M |
|
|
5
FibroGen
FGEN
$47.8M
| $68.3M | 6.9% | 1,511,785 +1,343,403 | +798% | +$60.7M |
|
|
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $62.9M | 6.35% | 614,128 +85,128 | +16% | +$8.72M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $61.6M | 6.22% | 597,711 -402,289 | -40% | -$41.4M |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $52.2M | 5.28% | 3,316,407 | – | – |
|
9
Ironwood Pharmaceuticals
IRWD
$214M
| $51.1M | 5.16% | 4,671,408 +274,240 | +6% | +$3M |
|
|
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $44.9M | 4.54% | +2,266,804 | New | +$44.9M |
|
11
Ultragenyx Pharmaceutical
RARE
$2.89B
| $31.6M | 3.19% | 497,899 | – | – |
|
|
PRVL
12
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $31.6M | 3.19% | +2,392,556 | New | +$31.6M |
|
|
BCEL
13
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $28M | 2.83% | +1,486,979 | New | +$28M |
|
|
CHMA
14
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $22.7M | 2.3% | 3,043,827 | – | – |
|
|
HARP
15
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $17.5M | 1.77% | 1,348,423 +12,000 | +0.9% | +$156K |
|
16
Gossamer Bio
GOSS
$562M
| $17.1M | 1.73% | 772,096 | – | – |
|
|
ARQL
17
DELISTED
Arqule Inc
ARQL
| $14.3M | 1.45% | +1,300,000 | New | +$14.3M |
|
|
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $12M | 1.22% | 1,136,043 -459,600 | -29% | -$4.87M |
|
19
Arcus Biosciences
RCUS
$1.13B
| $11.8M | 1.19% | 1,488,205 +498,059 | +50% | +$3.94M |
|
|
UBX
20
DELISTED
Unity Biotechnology
UBX
| $9.92M | 1% | 1,044,500 +137,886 | +15% | +$1.31M |
|
21
Cyclerion Therapeutics
CYCN
$7.91M
| $8.89M | 0.9% | +776,206 | New | +$8.89M |
|
22
Prothena Corp
PRTA
$441M
| $7.65M | 0.77% | 723,300 -3,219 | -0.4% | -$34K |
|
|
RUBY
23
DELISTED
Rubius Therapeutics, Inc
RUBY
| $7.29M | 0.74% | 463,152 -183,076 | -28% | -$2.88M |
|
|
SURF
24
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $6.52M | 0.66% | 2,312,688 +49,200 | +2% | +$139K |
|
25
Mersana Therapeutics
MRSN
$36.5M
| $5.64M | 0.57% | 1,392,231 -907,769 | -39% | -$3.68M |
|